J&J’s Janssen has received approval from the FDA for the long-acting version of Risperdal Consta (risperidone) for the treatment of bipolar I disorder. Risperdal Consta was approved for schizophrenia in 2003.
Also benefitting from the announcement is Boston biotech Alkermes, which provides technology to make long lasting drugs.
Also benefitting from the announcement is Boston biotech Alkermes, which provides technology to make long lasting drugs.